Whitehawk Therapeutics, Inc.
Clinical trials sponsored by Whitehawk Therapeutics, Inc., explained in plain language.
-
New hope for Tough-to-Treat cancers: first human trial of targeted therapy begins
Disease control Recruiting nowThis is the first human study of HWK-016, a new targeted cancer drug designed to deliver chemotherapy directly to cancer cells. The trial will enroll 265 adults with advanced ovarian or endometrial cancers that have stopped responding to standard treatments. Researchers will test…
Phase: PHASE1 • Sponsor: Whitehawk Therapeutics, Inc. • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
New targeted cancer drug enters first human trials for Tough-to-Treat tumors
Disease control Recruiting nowThis is the first human study of a new experimental cancer drug called HWK-007. Researchers are testing it in adults with advanced ovarian, endometrial, or non-small cell lung cancers that have stopped responding to standard treatments. The main goals are to find the safest dose …
Phase: PHASE1 • Sponsor: Whitehawk Therapeutics, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC